These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8551986)

  • 21. Biological activity of two humanized antibodies against two different breast cancer antigens and comparison to their original murine forms.
    Ceriani RL; Blank EW; Couto JR; Peterson JA
    Cancer Res; 1995 Dec; 55(23 Suppl):5852s-5856s. PubMed ID: 7493359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin.
    Khawli LA; Mizokami MM; Sharifi J; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2002 Aug; 17(4):359-70. PubMed ID: 12396700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.
    Ternant D; Azzopardi N; Raoul W; Bejan-Angoulvant T; Paintaud G
    Clin Pharmacokinet; 2019 Feb; 58(2):169-187. PubMed ID: 29802542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surfactant solutions and porous substrates: spreading and imbibition.
    Starov VM
    Adv Colloid Interface Sci; 2004 Nov; 111(1-2):3-27. PubMed ID: 15571660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimation of population pharmacokinetic parameters using destructively obtained experimental data: a simulation study of the one-compartment open model.
    Lindstrom FT; Birkes DS
    Drug Metab Rev; 1984; 15(1-2):195-264. PubMed ID: 6745082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Model building in pharmacokinetics/Part II: Generalized theoretical presentation of complete integration of linear compartment models of optional structure (author's transl)].
    Wolf M; Heinzel G; Koss FW; Bozler G
    Arzneimittelforschung; 1977; 27(4a):900-4. PubMed ID: 577857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysing saturable antibody binding based on serum data and pharmacokinetic modelling.
    Kletting P; Kiryakos H; Reske SN; Glatting G
    Phys Med Biol; 2011 Jan; 56(1):73-86. PubMed ID: 21119226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic modeling of radiolabeled antibody distribution in man.
    Rescigno A; Bushe H; Brill AB; Rusckowski M; Griffin TW; Hnatowich DJ
    Am J Physiol Imaging; 1990; 5(4):141-50. PubMed ID: 2090165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS.
    Zingmark PH; Edenius C; Karlsson MO
    Br J Clin Pharmacol; 2004 Oct; 58(4):378-89. PubMed ID: 15373930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma.
    Rosenblum MG; Murray JL; Haynie TP; Glenn HJ; Jahns MF; Benjamin RS; Frincke JM; Carlo DJ; Hersh EM
    Cancer Res; 1985 May; 45(5):2382-6. PubMed ID: 3986780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy.
    Bischoff KB
    Cancer Chemother Rep; 1975; 59(4):777-93. PubMed ID: 1175169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.
    Meno-Tetang GM; Lowe PJ
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):182-92. PubMed ID: 15733213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A general algorithm for radioactive decay with branching and loss from a medium.
    Strenge DL
    Health Phys; 1997 Dec; 73(6):953-7. PubMed ID: 9373074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans.
    Odom-Maryon TL; Williams LE; Chai A; Lopatin G; Liu A; Wong YC; Chou J; Clarke KG; Raubitschek AA
    J Nucl Med; 1997 Dec; 38(12):1959-66. PubMed ID: 9430477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.
    Fujimori K; Covell DG; Fletcher JE; Weinstein JN
    J Nucl Med; 1990 Jul; 31(7):1191-8. PubMed ID: 2362198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys.
    Co MS; Baker J; Bednarik K; Janzek E; Neruda W; Mayer P; Plot R; Stumper B; Vasquez M; Queen C; Loibner H
    Cancer Res; 1996 Mar; 56(5):1118-25. PubMed ID: 8640770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin.
    He XY; Xu Z; Melrose J; Mullowney A; Vasquez M; Queen C; Vexler V; Klingbeil C; Co MS; Berg EL
    J Immunol; 1998 Jan; 160(2):1029-35. PubMed ID: 9551944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications.
    Ferl GZ; Theil FP; Wong H
    Biopharm Drug Dispos; 2016 Mar; 37(2):75-92. PubMed ID: 26461173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneity of monoclonal antibody distribution and radiation dose in tumors: a modeling analysis.
    Fujimori K
    Hokkaido Igaku Zasshi; 1991 May; 66(3):369-84. PubMed ID: 1885162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A population pharmacokinetic model with time-dependent covariates measured with errors.
    Li L; Lin X; Brown MB; Gupta S; Lee KH
    Biometrics; 2004 Jun; 60(2):451-60. PubMed ID: 15180671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.